Growth Stocks

Although growth stock picks can be highly volatile, they can make good long-term investments. They may be well-known stars or quiet gems, but they do share one common attribute—they are growing at a higher-than-average rate within their industry, or within the market as a whole, and could keep growing for years or decades.

And keep in mind that we focus on growth stocks, which have a good long-term history and favourable prospects. We downplay momentum stocks that tend to attract many investors simply because they are moving faster than the market averages, but are liable to fall sharply when their momentum fades.

There’s room for growth stock investing in your portfolio, but make sure you follow our TSI Network three-part Successful Investor strategy for your overall portfolio:

  1. Invest mainly in well-established companies;
  2. Spread your money out across most if not all of the five main economic sectors (Manufacturing & Industry; Resources & Commodities; Consumer; Finance; Utilities);
  3. Downplay or avoid stocks in the broker/media limelight.

Make better stock picks when you read this FREE Special Report, Canadian Growth Stocks: WestJet Stock, RioCan Stock and More.

Read More Close
Growth Stocks Library Archives
Real estate services provider FirstService hit a record high of $290 in September 2025, but has since declined 26%. That’s partly because a lack of severe weather events has hurt demand for its roofing and building restoration services. We still like the company’s long-term prospects given recent acquisitions should spur its earnings.
U.S. tariffs on Canadian imports, including steel, aluminum, and crude oil, have raised risks for these companies—all three depend heavily on the U.S. for revenue. Uncertainty over the future of the U.S.-Mexico-Canada Agreement (USMCA) only compounds those concerns. Even so, we believe all three remain compelling long-term buys, as each provide essential products and services that are difficult for customers to substitute.
LOBLAW COMPANIES, $67.00, is a buy. The retailer (Toronto symbol L; Shares o/s: 1.2 billion; Market cap: $74.3 billion; TSINetwork Rating: Above Average; Yield: 0.8%; loblaw.ca) operates 1,160 supermarkets under several banners, including Loblaws, Zehrs, Provigo, Real Canadian Superstore and No Frills. It also owns the Shoppers Drug Mart chain, which has 1,363 drugstores across Canada.
CPKC and Metro are leading competitors in their respective markets. You can expect that to lower your risk going forward despite continuing economic uncertainty. We see both stocks as buys.
CANADIAN PACIFIC KANSAS CITY, $108.71, is a buy. The company (Toronto symbol CP; shares o/s: 897.7 million; Market cap: $92.1 billion; Rating: Above Average; Yield: 0.8%) took its current form in 2023 when it acquired U.S.-based Kansas City Southern (KCS) for $31 billion U.S.
NCR ATLEOS CORP. $36 (www.ncratleos.com) is a hold. On October 16, 2023, the old NCR Corp. (New York symbol NCR) split itself into two separate firms. One (NCR Atleos) focuses on automated teller machines; the other one (NCR Voyix, see below) caters to digital commerce businesses. At the time of the split, investors received one share of NCR Atleos for every two NCR shares they held. The NCR Atleos shares are now up 70% since the split, partly due to strong demand for ATM maintenance and software updates. However, the market’s ongoing shift from ATMs to online banking adds risk.
A solid way to gain exposure to the fast-growing artificial intelligence industry is through established technology companies such as Cisco Systems. Its networking products are essential to the development and operation of new AI services and software. In addition, Cisco’s own software business provides steady, recurring revenue, which helps to reduce its risk. CISCO SYSTEMS INC. $79 is a buy. The company (Nasdaq symbol CSCO; Aggressive Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 4.0 billion; Market cap: $316.0 billion; Price-to-sales ratio: 5.5; Dividend yield: 2.1%; TSINetwork Rating: Average; www.cisco.com) is a leading maker of products that link and manage computer networks.
ADOBE INC. $300 remains a buy for aggressive investors. The software company (Nasdaq symbol ADBE; Aggressive Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 410.5 million; Market cap: $123.2 billion; Price-to-sales ratio: 5.3; No dividends paid since June 2005; TSINetwork Rating: Average; www.adobe.com) makes programs that let computer users create, edit and share documents in the popular PDF format. It also makes a variety of electronic-publishing programs.
BECTON DICKINSON & CO. $202 is a buy. The medical device maker (New York symbol BDX; Conservative Growth Portfolio, Manufacturing sector; Shares outstanding: 285.2 million; Market cap: $57.6 billion; Price-to-sales ratio: 2.5; Dividend yield: 2.1%; TSINetwork Rating: Above Average; www.bd.com) plans to expand glass syringe production at its Columbus, Nebraska, facility. That positions the company to benefit from rising demand for GLP-1 weight-loss drugs and other injectable medicines. Becton expects to complete the $110 million project by mid-2026.
IDEXX LABORATORIES INC. $688 is a hold. The company (Nasdaq symbol IDXX; Aggressive Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 80.4 million; Market cap: $55.3 billion; Price-to-sales ratio: 13.6; No dividends paid; TSINetwork Rating: Average; www.idexx.com) makes equipment that veterinarians use to detect disease in animals. Back in 2024, Idexx launched its inVue Dx analyzer, which delivers blood test results in under 10 minutes. The device is in strong demand, and management raised its 2025 delivery target to 5,500 units from 4,500.
These two makers of testing equipment are doing a good job tapping into key trends. Agilent is seeing strong demand from developers of new GLP-1 weight loss drugs, while demand for new chips to run artificial intelligence programs is driving demand for Keysight’s chip-testing gear. We still see both as aggressive buys. AGILENT TECHNOLOGIES INC. $134 is a buy. The company (New York symbol A; Aggressive Growth Portfolio, Manufacturing sector; Shares outstanding: 283.5 million; Market cap: $38.0 billion; Price-to-sales ratio: 5.6; Dividend yield: 0.8%; TSINetwork Rating: Average; www.agilent.com) makes specialized testing equipment for medical research laboratories and industrial clients.